~~<i id='4569FBABBC'><strike id='4569FBABBC'><tt id='4569FBABBC'><pre id='4569FBABBC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

hotspot

author：hotspot 2025-10-02 22:39:54 - browse：2

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Element Biosciences CEO lays out genome sequencing strategy

Wikipedia

hotspot

entertainment

knowledge

entertainment

Wikipedia

Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb

WSS

After traumatic brain injury, life support decisions can use more time

Bird flu in milk supply is likely coming from asymptomatic cows

Alabama IVF ruling threatens families facing fatal genetic disease

He's a Nobel laureate. Critics say he was misleading on Covid

NIH study of ME/CFS points to clear biological hallmarks

Why palliative psychiatry is worth discussing

entertainment

hotspot

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Why does health care cost so much? A reading guide

Peter Hotez and the public health issue of online harassment

FTC falls short on scrutinizing hospital mergers, study says

Wildfire smoke exposes gaps in outdoor worker protections

Cholera vaccine supply gets boost as demand surges globally

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Medical leaders decry Supreme Court decision on affirmative action

New documents shed light on MD Anderson Cancer Institute feud

hotspot

Medical bills so high, Medicare adding extra digits to claim forms

Alabama IVF ruling threatens families facing fatal genetic disease

6 phony surgeries that take placebo to the extreme

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Cue Health's Covid

New documents shed light on MD Anderson Cancer Institute feud

entertainment

knowledge

entertainment

Wikipedia